SDC1 and neoplasm: LC53-0110 treatment showed accumulation of ubiquitinated proteins, inhibited cell viability with a low nM range potency in various tumor cell lines, and showed potent activity on CD138+ cells isolated from MM patients who are resistant/refractory to current FDA-approved drug treatment.